Collectively, these data confirm that PI3K pathway inhibition suppresses survival signaling and sensitizes GCB-DLBCL cells to a BCL-2/BCL-XL antagonist. This evidence concerns the gene BCL2L1 and diffuse large B-cell lymphoma.